초록

본 연구는 지난 5년간(2005년-2010년) 수산특정기술개발사업을 통하여 개발한 굴패각 이용기술을 근거로, 그 결과에서 확인된 관절염관련 항염증물질 (SJAI-003)과 구연산칼슘(SJP-Ca)소재의 개발과 복합 처방한 관절염 건기식 칼슘제를 개발하는데 있으며, SJAI-003소재에 대해서는 건기식 개별인정(관절 뼈건강)소재로 판매하기 위해 독성시험과 인체 적용시험을 실시하고 항염증소재(SJAI-003)과 구연산 칼슘제를 결합한 뼈와 건강에 도움을 주는 건기식 칼슘제를 개발하였다.

Abstract ▼

Anti-inflammatory efficacy from oyster shell in a SJAI-003 was isolated and dried to obtain a protein composition was analyzed and protein 1.63%, total sugar content 0.29%, 0.21% of reducing sugars, or other materials 97.87%, which was reacted with the anti-inflammatory, antioxidant, etc. bioactive

Anti-inflammatory efficacy from oyster shell in a SJAI-003 was isolated and dried to obtain a protein composition was analyzed and protein 1.63%, total sugar content 0.29%, 0.21% of reducing sugars, or other materials 97.87%, which was reacted with the anti-inflammatory, antioxidant, etc. bioactive lipid peroxidation was confirmed.
LPS in RAW 264.7 cells induced by treatment concentration of NO generation amount is SJAI-003 10~100 ㎍/ml, respectively, 125%, 120%, 110%, 101.7% measured as the concentration increases, the significant (p <0.05) production amount was reduced to NO, ROS generation rate also decreased dose-dependently.
SOD is a stress induced by LPS in RAW 264.7 cells when SJAI-003 was added to 10~50 ㎍/ml as the concentration increases, the significant (p <0.05) degree of its activity is increased. Catalase activity of the SJAI-003 10~100㎍/ml, depending on the treatment concentration dependently increased, GSH-px activities of 10~100 ㎍/ml concentration is increased to 3.41±0.04, 4.25±0.03, 4.57±0.02, 5.21±0.03 μM/mg protein/min to significantly (p <0.05) of its activity is increased. So SJAI-003 in RAW 264.7 cells treated with LPS-induced stress when, SJAI-003 by significantly increased the activity of antioxidant enzymes could see.
SJAI-003 is a pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) that inhibit the expression was confirmed that, NF-κB, iNOS and COX-2 expression was also dose-dependently reduced. Therefore, the SJAI-003 inhibited the expression of inflammatory mediators could be confirmed.
Through preclinical animal studies of cartilage constituents Proteoglycan (PG) content analysis of the articular cartilage papain treated control group compared with the normal group as much light tint does not dye or no dye or a loss of PG can be observed at a was, Diclofenac sodium(DS) treatment groups than in the control group, but rather papain treated lightly dyed dyed darker than the control group compared to the depth of the surface layer of cartilage was more densely stained than the PG layer was confirmed that this recovery. SJAI-003 treated group when compared with the normal group, the articular cartilage stained papain dosage range is decreased as compared with the control group than in a dark red-dyed PG layer is DS treated groups, as can be observed that the recovery.
Even if the by-product of the SJP-Ca rather than SJAI-003 dose-dependently PG layer is low, but it was confirmed to be restored.
Through the production process standardization reviewed the production yield SJAI-003 25g per 1kg of the oyster shell was found to be produced, by-product of about 1.8kg per kg of calcium citrate recovery is possible, and a purity of 98.0% or more was confirmed by.
Clinical trial test for toxicity and safety analysis of the size of the 4 ton reactor was used to produce the SJAI-003, this material safety assessment of the toxicity and clinical trial test was performed.
Biotoxtech firm commissioned by GLP toxicity studies showed that induced micronucleus test in mouse bone marrow cells, using a bacterial reverse mutation test, mammalian chromosome aberration test using cultured cells, Sprague-Dawley rats using a single oral dose toxicity studies in both to accept the voice judgment it was confirmed that there is no toxicity.
Men and women aged 40 to 75 years in patients with osteoarthritis and 12 weeks for a product containing SJAI-003 was orally. Osteoarthritis, and that the improvement of the efficacy and safety were evaluated.
The results of this study, the results are SJAI-003 TNF- and control groups α were not statistically significant differences between the (p=0.117). However, unlike SJAI-003 control group was statistically different from the change in blood glucose levels was confirmed that appears. This is a test food (SJAI-003) gave the judgment regulate insulin secretion, which have anti-inflammatory properties can be inferred. In this clinical trial test in one tablet with food (600mg) per main component of oyster shell extract (SJAI-003) determines the content of 150mg of view, oyster shell extract (SJAI-003) if you increase the dose of arthritis for a more improved effect statistically significant results may be expected.